Share
675 Posts.
lightbulb Created with Sketch. 150
clock Created with Sketch. 30/04/15
10:35
Share
Hi Jasetheace40,
Taken at face value, that preliminary statement would seem to highlight what OBJ thinks the tech is best designed for. We've had no significant announcement about a development/evaluation of vaccines or skin cancer drugs, yet those things get mentioned explicitly first? Why? I think we can fairly assume that these applications weren't simply plucked out of the air by Dr Edwards. I suspect OBJ has been working on such things with Pfizer and/or others for years, and it really is only a matter of time before some formal partnership is announced.
Expand
“We have completed the first of 3 clinical studies and in fact of those important with P&G before you ask no I can’t tell you what the outcomes of those are because the clinical results are not OBJ’s property” ~ Jeff Edwards, 2013 AGM has been announced any developments in this area apart from the results should be notified to shareholders, but if a trial is conducted with a “potential partner” would this be notified or remain confidential as no agreement is in place?
23 November 2004 OBJ moves to human Clinical Trials OBJ Limited (OBJ) announces that it has signed a clinical trial and drug delivery study contract with the Western Australian Biomedical Research Institute (WABRI). The contract, which includes the first volunteer human trial into the use of OBJ’s Dermaportation technology will commence immediately and run over a 40 week period . The 3-part program involves in-vitro studies into the enhanced transdermal (through the-skin) delivery of 10 and 12 commercially important drugs and local anaesthetics, as well as human clinical trials . The human trials will invoke an evaluation of OBJ’s micro-computer controlled transdermal delivery system to increase the speed of delivery and efficacy of locally applied anaesthetics. OBJ’s proprietary Dermaportation technology has previously been reported to increase transdermal transportation of caffeine by almost 500%. Caffeine is the standard compound for research and evaluation purposes, however OBJ will now focus on medically and commercially important drugs, therapeutic compounds and cosmetic agents OBJ has already been invited to presents its research findings at 4 major pharmaceutical, dermatological, cosmetic and scientific conferences, however the company anticipates an elevation in international interest once results start to emerge from the WABRI contract. OBJ receives approval for Vaccine and Anti-body drug patch trials OBJ Limited (OBJ) is pleased to announce that it has received Ethics Committee approval to commence animal trials to investigate the efficacy of its Dermaportation drug delivery technology in the development of a Vaccine and Anti-body drug patch . The approval provides OBJ with the ability to trial its technology as a means of delivering a number of key vaccines and anti-bodies through the skin, rather than by injection, as is currently the case. Inter-dermal delivery of vaccines has been shown to be up to 6 times more efficient than intra-muscular injections. This would allow more people to be immunised using current vaccine stocks or less vaccine being needed by an individual to create the same immunological response. Through-the-skin administration of drugs, vaccines and anti-bodies offers a number of additional commercial and social advantages, including over-the counter distribution plus safe and simple self-administration. A vaccine patch would also reduce the need for sterile conditions, highly trained staff and safety concerns relating to needle stick injuries. The vaccine and anti-body program will be conducted as an independent research program by Murdoch University, under the supervision of Dr Robin Jacobs. The company expects initial results by October 2005. OBJ’s DRUG DELIVERY TECHNOLOGY PROVEN IN HUMAN TRIAL …..Confirmation of efficacy in humans and clinical benefits with existing drugs at lower dosages are two key milestones for the company. The pilot study will be expanded to a full clinical trial later in the year at which time OBJ will seek to optimise the efficacy of its drug delivery technology by matching the delivery system to the molecular characteristics of the specific drug used
Expand
The above announcement [08.06.2005] led to a further announcement on Friday 11th, November, 2005 where it was disclosed that the Vaccine that was used was Glanvac, which is a Pfizer vaccine.
OBJ Limited (OBJ) announced today that results from the second phase of the Vaccine patch study had shown that the company’s through-the-skin Vaccine technology had achieved statistically significant results in an animal study that equalled those achieved by traditional injection methods. The final antibody analyses taken 2 weeks following the second or booster vaccination phase, showed that the lambs inoculated using the company’s active drug patch technology had resulted in similar or superior immunological response to those vaccinated using the traditional intra-muscular injection method
Expand
OBJ Limited (ASX:OBJ) is pleased to announce major developments in the commercialisation of its transdermal delivery technology, including the appointment of two of Australia’s pre-eminent medical scientists. Dr Ian Frazer and Dr Ken Donald have been appointed to assist with the new OBJ subsidiary OBJ Transdermal Vaccines (OBJTV), a vehicle that will develop OBJ’s unique technology for delivery of vaccines through the skin. Dr Frazer, the 2006 Australian of the Year and developer of the Gardasil cervical cancer vaccine, has been appointed to the Scientific Advisory Board of OBJ to advise on the vaccine project. Dr Donald, a pathologist and former head of the School of Medicine at the University of Queensland, has been appointed Chairman of OBJTV. Dr Gil Shearer, a dentist who is currently involved in teaching Endodontics at the University of Queensland, has been appointed as a Director and CEO of OBJTV. Dr Frazer and Dr Donald will oversee the development of the transdermal vaccine delivery system for OBJ’s first internal development program OBJ Chief Operating Officer Dr Leearne Hinch said the establishment of OBJTV and the appointments of Dr Frazer and Dr Donald represented a significant step forward for the company as it moves from the research phase to commercialisation of its unique technology. “The vaccine project is aimed at validating and developing the OBJ technology for vaccine delivery, ” said Dr Hinch. ”The program will be managed and supervised by a highly experienced scientific team and will draw upon the world-class facilities of the University of Queensland .” OBJTV intends to develop transdermal vaccines to preclinical stage before seeking a commercialisation partner. The vaccine development program has been established following recent successes for the Company’s pilot animal vaccine study and its positive results for transdermal delivery of therapeutic peptides in a skin diffusion study conducted by Curtin University in Western Australia ~ [15.08.2007]
Expand
Where still are keeping relatively away from long term deeply expensive pharmaceuticals activities ~ Jeff Edwards, 2013 AGM
PHARMACEUTICAL (THERAPEUTIC DRUG PATCHES AND DRUG DELIVERY DEVICES) Pharmaceutical developments are traditionally long term, high reward activities, however regulatory barriers and extended development and testing periods limits early cash flow potential, particularly in the pre ‐ clinical phases. OBJ is currently engaged in pharmaceutical drug patch evaluations with major international pharmaceutical companies, as announced to the market on 6 April 2010 ~ [13.05.2010]
Expand
But wait….what was that – “OBJ is currently engaged in pharmaceutical drug patch evaluations with major international pharmaceutical companies”, this couldn’t be Pfizer by any chance….
“OBJ is pleased to announce that 3M has confirmed its interest in working with OBJ’s current or potential clients in patch development and/or contract manufacturing following testing performed by 3M Drug Delivery System’s laboratory in St Paul Minnesota” Glyn Denison, Director of OBJ commented, "With the number of partners that OBJ is working with worldwide, it is important that OBJ has the ability to provide professional development and manufacturing facilities to the highest possible standard. Continuing our relationship with 3M fulfils that need and allows OBJ to offer a full range of development and production programs to partner projects supported by 3M Drug Delivery Systems technology and production expertise" ~ [06.04.2010]
Expand
26th April, 2012 Share Holder Update Micro-needles The Company has been working with the University of Queensland and in particular Dr Tarl Prow in the development of enhancing micro-needle performance with the addition of OBJ’s ETP magnetic technology. OBJ’s ETP technology, when integrated into a traditional micro-needle delivery system, showed substantially greater drug delivery than micro-needles alone. The resulting technology was the subject of a recent patent application MICRO-NEEDLES The Company’s work with the University of Queensland in enhancing the passage of drug from the skin into the viable epidermis following micro-needle application continues. The previous encouraging results by the University are now being developed into more potentially commercially focused diversification program 'Hello xxxxx, Thankyou for your email. We have undertaken internal tests where we have used micro needles in addition to the OBJ ETP technology with very strong results so yes it is an alternative. But at this time, our research commitments are quite demanding from the many programs underway and we remain focused on delivering these programs. Perhaps in the future we may revisit the concept but at this time we must remain focused on what we have in hand. Thanks for the consideration and appreciate your interest in potential applications. Kind Regards, ~ cmk1969 [19.10.2013]
Expand
From the reply that cmk1969 received on the 19.10.2013 no mention is made of the results from the University QLD that were conducted in 2012 …..
Pfizer Spins Off Animal Health Unit in $2.2 Billion I.P.O. January 31, 2013 Making medicines for livestock and pets may not seem to be as sexy a business as social networking, but Pfizer’s animal health unit is poised to enjoy the biggest stock market debut since Facebook’s offering last spring.The Pfizer division, known as Zoetis, raised $2.2 billion in its initial public offering on Thursday, exceeding expectations by pricing its stock at $26 a share, above the expected range of $22 to $25 a share. The sale values the company at about $13 billion Anticipation began building last summer, when Pfizer announced plans to spin off its animal health division as part of an effort to slim down. Under its chief executive, Ian Read, the drug giant has refocused on its core business of developing new medicines. That has meant selling or spinning off divisions that the company deems nonessential, an effort that included selling an infant nutrition business to Nestlé for $11.9 billion last April. Pfizer executives explored a sale of Zoetis — whose name springs from the word “zoetic,” meaning “pertaining to life” — last year. But it decided that the fast-growing division was better off as a publicly traded company. http://dealbook.nytimes.com/2013/01/31/pfizer-spins-off-animal-health-unit-in-2-2-billion-i-p-o/?_r=0
Expand
(20min delay)